2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Myelodysplastic Syndromes
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Acute
9
Leukemia
9
Hematologic Neoplasms
7
Lymphoma, Non-Hodgkin
6
Lymphoma
6
Multiple Myeloma
4
Primary Immunodeficiency Diseases
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Immunoproliferative Disorders
3
Immune System Diseases
3
Hodgkin Disease
3
Cytopenia
3
Anemia, Aplastic
3
Thalassemia
2
Osteopetrosis
2
Neoplasm, Residual
2
Neoplasm Metastasis
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Hemoglobinopathies
2
Fanconi Anemia
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Anemia, Sickle Cell
2
Anemia, Diamond-Blackfan
2
Anemia
2
Uveal Melanoma
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Interventions
Cyclophosphamide
7
pembrolizumab
6
Radiotherapy
6
Cisplatin
6
Sunitinib
5
Carboplatin
5
Paclitaxel
4
Thymectomy
3
130-nm albumin-bound paclitaxel
3
selinexor
2
lenvatinib
2
fludarabine
2
Taxes
2
Robotic Surgical Procedures
2
Ramucirumab
2
Prednisone
2
Pemetrexed
2
Octreotide
2
Nivolumab
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Imatinib Mesylate
2
Etoposide
2
Erlotinib Hydrochloride
2
Drug Therapy
2
Doxorubicin
2
Chemoradiotherapy
2
Celecoxib
2
zimberelimab
1
vorolanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thymoma
×
AP 1903 reagent
×
Clear all
NCT07598955
2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled